Trials / Completed

CompletedNCT00366431

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Non-Malignant Pain

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 420 (planned)

Sponsor: Bausch Health Americas, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.

Conditions

Constipation

Interventions

Type	Name	Description
DRUG	MOA-728

Timeline

Start date: 2006-08-01
Completion: 2007-03-01
First posted: 2006-08-21
Last updated: 2019-11-25

Locations

67 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00366431. Inclusion in this directory is not an endorsement.